[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594333":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":16,"centralContacts":21,"locations":29,"responsibleParty":68,"collaborators":70,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":7,"enrollmentInfo":87,"targetDuration":7,"studyType":90,"phases":7,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":32,"whyStopped":7,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",null,[9,13],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","RS ratio","We will evaluate the non-culture, sputum-based assay RS ratio, which measures ongoing Mycobacterium tuberculosis activity by quantifying the abundance of precursor rRNA relative to mature rRNA (an indicator of active rRNA synthesis).",{"type":10,"name":14,"description":15,"armGroupLabels":7,"otherNames":7},"Blood-based host immune response assays","We will evaluate blood-based assays measuring host immune response parameters for predicting mycobacterial activity.",[17],{"name":18,"affiliation":19,"role":20},"Adithya Cattamanchi, MD","University of California San Francisco; University of California Irvine","PRINCIPAL_INVESTIGATOR",[22,26],{"name":18,"role":23,"phone":24,"phoneExt":7,"email":25},"CONTACT","415-206-5489","adithya.cattamanchi@ucsf.edu",{"name":27,"role":23,"phone":7,"phoneExt":7,"email":28},"Sophie Huddart, PhD","Sophie.Huddart@ucsf.edu",[30,46,53],{"facility":31,"status":32,"city":33,"state":7,"zip":7,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Kisenyi Health Center","RECRUITING","Kampala","Uganda","UG",{"type":37,"coordinates":38},"Point",[39,40],32.58219,0.31628,{"lat":40,"lon":39},[43],{"name":44,"role":23,"phone":7,"phoneExt":7,"email":45},"William Worodria","worodria@yahoo.com",{"facility":47,"status":32,"city":33,"state":7,"zip":7,"country":34,"countryCode":35,"cosmosGeoPoint":48,"geoPoint":50,"contacts":51},"Mulago Outpatient Department",{"type":37,"coordinates":49},[39,40],{"lat":40,"lon":39},[52],{"name":44,"role":23,"phone":7,"phoneExt":7,"email":45},{"facility":54,"status":55,"city":56,"state":7,"zip":7,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Hanoi Lung Hospital, Outpatient departments","NOT_YET_RECRUITING","Hanoi","Vietnam","VN",{"type":37,"coordinates":60},[61,62],105.84117,21.0245,{"lat":62,"lon":61},[65],{"name":66,"role":23,"phone":7,"phoneExt":7,"email":67},"Ha Phan","Ha.Phan@ucsf.edu",{"type":69,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[71,73,75],{"name":72,"class":6},"University of California, Irvine",{"name":74,"class":6},"University of Colorado, Denver",{"name":76,"class":77},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH","100594333","candidate-clinical-correlate-of-prognostic-outcome-for-tb-study-100594333",false,"NCT07018076","Candidate Clinical Correlate of Prognostic Outcome for TB Study","C3PO","Inclusion Criteria:\n\n1. . individuals age ≥ 12 years;\n2. . have completed treatment for drug-susceptible tuberculosis with the standard 6-month regimen of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE).\n\nExclusion Criteria:\n\n1. completed treatment for drug-susceptible tuberculosis \\>14 days prior to screening\u002Fenrollment;\n2. routinely taking any medication with anti-mycobacterial activity (including fluoroquinolones) for any reason not related to tuberculosis treatment within the last 14 days;\n3. unwilling to provide informed consent or return for study follow-up visits.","ALL","12 Years",{"count":88,"type":89},750,"ESTIMATED","OBSERVATIONAL","As part of the ongoing efforts within the Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) study, the Candidate Clinical Correlate as Prognostic Outcome for TB (C3PO) study serves as a supplement aimed at evaluating predictors and novel biomarkers of recurrent TB among TB survivors. Current tools for predicting TB recurrence risk are suboptimal, limiting the ability to assess new TB treatment regimens effectively. Identifying accurate sputum- or blood-based biomarkers for recurrence risk could significantly improve the efficiency and informativeness of Phase 2 and 3 clinical trials.",[93],"Tuberculosis",[93,95,96],"Global Health","Diagnostics","2026-07-16",{"date":99,"type":100},"2026-07-20","ACTUAL",{"date":102,"type":100},"2025-11-25",{"date":104,"type":89},"2027-05-31",{"name":5,"class":6},3]